Federica Bianchi graduated in natural science at the University of Pisa and got the international PhD in structural biology at CERM, the center for magnetic resonance of the University of Florence in collaboration with GSK of Siena.

She maturated a strong experience in cancer therapy working either in high profile organization as Dana Farber in Boston, GSK and Astrazeneca, either in emerging and innovative small company.  Experience enriched by an international background developed in USA, Ireland, Italy, Uk and Singapore.

During her career she has specialized in the development of anti-tumor therapies with monoclonal antibodies from the identification of new candidates, sequencing, production and characterization in terms of affinity, antigen specificity, functionality, purity, stability, structure resolution at atomic level by crystallography and engineering  to validation in the CMC environment.

Furthermore, he contributed to the development of microfluidics devices for the high throughput screening of primary cells for the identification of new monoclonal antibodies and more marginally for cell therapies.

Since December 2024 Federica has joined the Checkmab team as a molecular and cellular biologist to support the identification of new therapeutic antibodies.